Portlock C S, Rosenberg S A
Cancer. 1976 Mar;37(3):1275-82. doi: 10.1002/1097-0142(197603)37:3<1275::aid-cncr2820370307>3.0.co;2-m.
From July 1971 to July 1974, 58 patients with advanced non-Hodgkin's lymphomas were treated with cyclophosphamide, vincristine, prednisone (CVP) at Stanford Medical Center. Utilizing the histopathologic criteria of Rappaport el al., response to CVP was found to be significantly better in the nodular (96.6%) and the diffuse lymphocytic (100%) histologies as compared to the diffuse nonlymphocytic lymphomas (47.6%). A pathologically documented complete remission was obtained in 33.9% of patients and all but two remain disease free for periods of 2-28 months. Concurrent bleomycin was administered to 17 patients during CVP therapy and no improvement in response or median survival was noted. Prior radiation therapy delivered to 21 patients did not adversely affect their response to CVP or their survival. Splenectomy in 17 patients prior to CVP did not improve hematologic tolerance to chemotherapy except in those patients with prior radiation therapy, and there was no improvement in response to CVP or survival. CVP is effective in achieving complete remissions and extended disease-free survivals in advanced non-Hodgkin's lymphomas; both a nodular architecture and a diffuse lymphocytic histology are positive determinants for response to chemotherapy and improved median survival.
1971年7月至1974年7月，斯坦福医学中心对58例晚期非霍奇金淋巴瘤患者采用环磷酰胺、长春新碱、泼尼松（CVP）进行治疗。根据拉帕波特等人的组织病理学标准，发现与弥漫性非淋巴细胞性淋巴瘤（47.6%）相比，结节性（96.6%）和弥漫性淋巴细胞性（100%）组织学类型对CVP的反应明显更好。33.9%的患者获得了病理记录的完全缓解，除两名患者外，所有患者在2至28个月内均无疾病。在CVP治疗期间，17例患者同时接受了博来霉素治疗，但未观察到反应或中位生存期有所改善。21例患者之前接受过放射治疗，这并未对他们对CVP的反应或生存期产生不利影响。17例患者在CVP治疗前进行了脾切除术，除了那些之前接受过放射治疗的患者外，并未提高对化疗的血液学耐受性，对CVP的反应或生存期也没有改善。CVP对于晚期非霍奇金淋巴瘤实现完全缓解和延长无病生存期是有效的；结节状结构和弥漫性淋巴细胞组织学都是化疗反应和改善中位生存期的积极决定因素。
